PSNL - Here's Why Liquid Biopsy Stocks Fell as Much as 39.2% in September
Thanks to a handful of initial public offerings (IPOs) in the last year, individual investors can now own liquid biopsy stocks. Thanks to awful performance last month, most of them are trading at their lowest levels in months -- or ever.
Shares of Adaptive Biotechnologies (NASDAQ: ADPT) fell over 39% last month, according to data provided by S&P Global Market Intelligence. That was followed by a decline of 27.1% for shares of Guardant Health (NASDAQ: GH) and a tumble of 24.2% for shares of Personalis (NASDAQ: PSNL).
Adaptive Biotechnologies and Personalis, both of which went public in June, are trading at all-time lows. Guardant Health is trading at its lowest level since early 2019. The stocks appear to have simply cooled off following unchecked enthusiasm for the industry as a whole. What should investors make of the recent slides?